Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392918 | 0.93 | RAB9A (0.65) | RAB9AHDAC1HDAC6TDP1TSHR | |
| SCHEMBL4928557 | 0.93 | KDM4E (0.54) | RAB9AHDAC1HDAC6TDP1TSHR | |
| SCHEMBL5409793 | 0.92 | RAB9A (0.54) | RAB9AHDAC1HDAC6NPC1HPGD | |
| SCHEMBL5397479 | 0.92 | HDAC1 (0.61) | RAB9AHDAC1HDAC6TDP1NPC1 | |
| SCHEMBL5407093 | 0.92 | HDAC1 (0.61) | RAB9AHDAC1HDAC6TDP1NPC1 | |
| SCHEMBL5392370 | 0.91 | HDAC1 (0.55) | RAB9AHDAC1HDAC6TDP1NPC1 | |
| SCHEMBL5403175 | 0.91 | HDAC1 (0.59) | RAB9AHDAC1HDAC6TDP1NPC1 | |
| SCHEMBL5406209 | 0.90 | RAB9A (0.54) | RAB9AHDAC1HDAC6TDP1TSHR | |
| SCHEMBL5409746 | 0.90 | RAB9A (0.54) | RAB9AHDAC1HDAC6TDP1NPC1 | |
| SCHEMBL5397034 | 0.90 | RAB9A (0.69) | RAB9AHDAC1HDAC6TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | RAB9A 3132/4885HDAC1 2189/4885HDAC6 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.